Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
CSL ( (AU:CSL) ) just unveiled an update.
CSL Limited announced the cessation of 7,194 securities due to the lapse of conditional rights, as the conditions were not met or became incapable of being satisfied. This announcement may impact CSL’s issued capital structure and reflects the company’s ongoing adjustments to its financial and operational strategies.
The most recent analyst rating on (AU:CSL) stock is a Buy with a A$325.00 price target. To see the full list of analyst forecasts on CSL stock, see the AU:CSL Stock Forecast page.
More about CSL
CSL Limited operates in the biotechnology industry, focusing on the development and delivery of innovative medicines that save lives and improve the quality of life for people with rare and serious diseases. The company is a global leader in plasma-derived therapies and influenza vaccines, with a strong market presence in these areas.
YTD Price Performance: -13.10%
Average Trading Volume: 854,234
Technical Sentiment Signal: Sell
Current Market Cap: A$117.5B
See more data about CSL stock on TipRanks’ Stock Analysis page.